Pioneering excellence in the field of immunotherapy
Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers and other serious conditions. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer, endometriosis and neuropathologies.
Developing more precise and more accessible treatment alternatives for patients with solid cancers
Cartherics develops innovative and precisely-defined immunotherapy treatments to control a variety of cancers and endometriosis. We take a multi-platform approach combining the best components of immune defences utilising gene editing and CAR technology.
Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.
Our Technology
Novel “off-the-shelf” immune therapy
Cartherics is developing its novel “off-the-shelf” (allogeneic) immune therapy products for the treatment of cancer and endometriosis based on immune killer cells and extracellular vesicles (EVs or exosomes) extracted from there immune cells. The company is developing large-scale manufacture of these CAR-iNK cells and EVs for application in human trials.
Our technology seeks to harness the power of Natural Killer (NK) cells, T cells & macrophages within the immune system, to fight against solid tumours and endometriosis. We’re researching a portfolio of allogeneic therapies that increase safety, efficacy and accessibility compared to existing CAR-T and other immune therapies.
Our Expertise
From labs to marketplace
Our strong background in successful research, development, clinical testing and commercialisation of pharmaceutical products and medical services makes us exceptionally well placed to drive an innovative company achieving successful clinical and commercial outcomes.
NK, T cell and macrophage specialisation
- Stem cell research
- Preclinical immunotherapy R&D
- Advanced clinic grade immune cell manufacture
- Oncology
Endometriosis
Alzheimer’s Disease
Clinical trials management
- Strategic partnerships
- International experience
- Product commercialisation
- Business development / licensing
- Grant acquisition
- Financing
